Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial.
Joensuu, Heikki ; Eriksson, Mikael LU
; Sundby Hall, Kirsten
; Reichardt, Annette
; Hartmann, Jörg T
; Pink, Daniel
; Ramadori, Giuliano
; Hohenberger, Peter
; Al-Batran, Salah-Eddin
and Schlemmer, Marcus
, et al.
(2016)
In Journal of Clinical Oncology
34(3).
p.244-250
- Abstract
- Three years of adjuvant imatinib therapy are recommended for patients with GI stromal tumor (GIST) with high-risk features, according to survival findings in the Scandinavian Sarcoma Group XVIII/AIO (Arbeitsgemeinschaft Internistische Onkologie) trial. To investigate whether the survival benefits have persisted, we performed the second planned analysis of the trial.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/8243484
- author
- Joensuu, Heikki
; Eriksson, Mikael
LU
; Sundby Hall, Kirsten
; Reichardt, Annette
; Hartmann, Jörg T
; Pink, Daniel
; Ramadori, Giuliano
; Hohenberger, Peter
; Al-Batran, Salah-Eddin
and Schlemmer, Marcus
, et al. (More)
- Joensuu, Heikki
; Eriksson, Mikael
LU
; Sundby Hall, Kirsten
; Reichardt, Annette
; Hartmann, Jörg T
; Pink, Daniel
; Ramadori, Giuliano
; Hohenberger, Peter
; Al-Batran, Salah-Eddin
; Schlemmer, Marcus
; Bauer, Sebastian
; Wardelmann, Eva
; Nilsson, Bengt
; Sihto, Harri
; Bono, Petri
; Kallio, Raija
; Junnila, Jouni
; Alvegård, Thor
LU
and Reichardt, Peter
(Less)
- organization
- publishing date
- 2016
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Journal of Clinical Oncology
- volume
- 34
- issue
- 3
- pages
- 244 - 250
- publisher
- American Society of Clinical Oncology
- external identifiers
-
- pmid:26527782
- scopus:84955616130
- wos:000374331100012
- pmid:26527782
- ISSN
- 1527-7755
- DOI
- 10.1200/JCO.2015.62.9170
- language
- English
- LU publication?
- yes
- id
- 2997816b-44eb-4b71-9d3f-a21e14b68365 (old id 8243484)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/26527782?dopt=Abstract
- date added to LUP
- 2016-04-04 08:46:21
- date last changed
- 2022-04-23 17:53:55
@article{2997816b-44eb-4b71-9d3f-a21e14b68365,
abstract = {{Three years of adjuvant imatinib therapy are recommended for patients with GI stromal tumor (GIST) with high-risk features, according to survival findings in the Scandinavian Sarcoma Group XVIII/AIO (Arbeitsgemeinschaft Internistische Onkologie) trial. To investigate whether the survival benefits have persisted, we performed the second planned analysis of the trial.}},
author = {{Joensuu, Heikki and Eriksson, Mikael and Sundby Hall, Kirsten and Reichardt, Annette and Hartmann, Jörg T and Pink, Daniel and Ramadori, Giuliano and Hohenberger, Peter and Al-Batran, Salah-Eddin and Schlemmer, Marcus and Bauer, Sebastian and Wardelmann, Eva and Nilsson, Bengt and Sihto, Harri and Bono, Petri and Kallio, Raija and Junnila, Jouni and Alvegård, Thor and Reichardt, Peter}},
issn = {{1527-7755}},
language = {{eng}},
number = {{3}},
pages = {{244--250}},
publisher = {{American Society of Clinical Oncology}},
series = {{Journal of Clinical Oncology}},
title = {{Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial.}},
url = {{http://dx.doi.org/10.1200/JCO.2015.62.9170}},
doi = {{10.1200/JCO.2015.62.9170}},
volume = {{34}},
year = {{2016}},
}